GALAPAGOS NV/S (NASDAQ:GLPG) Given Outperform Rating at Credit Suisse Group

Credit Suisse Group reaffirmed their outperform rating on shares of GALAPAGOS NV/S (NASDAQ:GLPG) in a research note published on Wednesday morning, Briefing.com Automated Import reports.

A number of other brokerages have also recently issued reports on GLPG. HC Wainwright set a $10.00 target price on Jaguar Health and gave the stock a buy rating in a report on Tuesday, July 2nd. Zacks Investment Research cut ExlService from a hold rating to a sell rating in a report on Wednesday. ValuEngine upgraded XPO Logistics from a strong sell rating to a sell rating in a report on Thursday, April 4th. Cantor Fitzgerald restated a buy rating and issued a $25.00 target price on shares of Menlo Therapeutics in a report on Thursday, May 2nd. Finally, BidaskClub cut Amyris from a hold rating to a sell rating in a report on Thursday, June 27th. One analyst has rated the stock with a hold rating, eleven have given a buy rating and three have assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average target price of $134.90.

Shares of NASDAQ GLPG opened at $145.75 on Wednesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.31 and a current ratio of 6.31. The stock has a fifty day moving average of $125.33. GALAPAGOS NV/S has a 52-week low of $85.00 and a 52-week high of $146.13.

GALAPAGOS NV/S (NASDAQ:GLPG) last issued its earnings results on Friday, April 26th. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.19) by $0.18. The business had revenue of $46.47 million for the quarter, compared to analysts’ expectations of $44.92 million. GALAPAGOS NV/S had a negative return on equity of 3.60% and a negative net margin of 13.24%. As a group, research analysts expect that GALAPAGOS NV/S will post -4.61 EPS for the current fiscal year.

Several hedge funds have recently modified their holdings of the company. Comerica Bank grew its stake in shares of GALAPAGOS NV/S by 6.3% in the 4th quarter. Comerica Bank now owns 3,120 shares of the biotechnology company’s stock valued at $325,000 after purchasing an additional 185 shares during the period. Bank of New York Mellon Corp grew its stake in shares of GALAPAGOS NV/S by 530.8% in the 4th quarter. Bank of New York Mellon Corp now owns 249,137 shares of the biotechnology company’s stock valued at $22,857,000 after purchasing an additional 209,642 shares during the period. D. E. Shaw & Co. Inc. grew its stake in shares of GALAPAGOS NV/S by 354.6% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 19,093 shares of the biotechnology company’s stock valued at $1,752,000 after purchasing an additional 14,893 shares during the period. OLD Mission Capital LLC grew its stake in shares of GALAPAGOS NV/S by 103.2% in the 4th quarter. OLD Mission Capital LLC now owns 34,209 shares of the biotechnology company’s stock valued at $3,138,000 after purchasing an additional 17,378 shares during the period. Finally, Macquarie Group Ltd. grew its stake in shares of GALAPAGOS NV/S by 2.7% in the 4th quarter. Macquarie Group Ltd. now owns 7,768 shares of the biotechnology company’s stock valued at $713,000 after purchasing an additional 202 shares during the period. Institutional investors and hedge funds own 16.33% of the company’s stock.

About GALAPAGOS NV/S

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.

Featured Story: What is Considered a Good Return on Equity (ROE)?

Analyst Recommendations for GALAPAGOS NV/S (NASDAQ:GLPG)

Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.